PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.40%
Both companies show declining cash positions (-13.40% vs AGEN's -13.65%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.40%
Similar yoy growth to AGEN's -13.65%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.47%
Similar yoy growth to AGEN's -12.21%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
8.92%
Similar yoy growth to AGEN's 8.34%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.91%
≥ 1.5x AGEN's 2.40%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
1.25-1.5x AGEN's -8.71%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
25.71%
Less than half of AGEN's -44.02%. David Dodd sees a more disciplined AP approach or lower volume.
-32.96%
Higher Short-Term Debt Growth compared to AGEN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.33%
Exceeding 1.5x AGEN's -13.68%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-28.78%
Less than half of AGEN's 8.03%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.78%
Less than half of AGEN's 3.02%. David Dodd sees far fewer liability expansions relative to competitor.
1.95%
Above 1.5x AGEN's 0.16%. Michael Burry suspects heavy new equity expansion or dilution.
-3.92%
Similar yoy to AGEN's -4.08%. Walter Schloss sees parallel earnings retention vs. competitor.
-19.50%
Less than half of AGEN's 26.23%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.72%
Below half AGEN's -37.15%. Michael Burry sees potential underperformance in building shareholder capital.
-12.20%
1.25-1.5x AGEN's -8.71%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Less than half of AGEN's 3.35%. David Dodd sees less overall debt expansion vs. competitor.
13.20%
Less than half of AGEN's 47.68%. David Dodd sees better deleveraging or stronger cash buildup than competitor.